Adare Pharmaceuticals has entered into an agreement with Egalet Corporation to acquire global rights of the Parvulet technology platform and its associated intellectual property (IP). The technology is protected by several patents granted in the U.S., Canada and Europe with patent life ranging from five to 10 years.   Using commonly used pharmaceutical excipients, the technology enables single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pe...